Neurocrine Biosciences | 销售和管理费用



Selling And Administration Expenses 更改 日
AbbVie USD 3.29B 562M 2025-03
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
ALKERMES USD 146.99M 3.39M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amgen USD 1.88B 253M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Cytokinetics USD 62.34M 5.69M 2024-12
Dynavax Technologies USD 41.58M 1.48M 2024-12
Exelixis USD 134.33M 22.53M 2025-01
Gilead Sciences USD 1.26B 603M 2025-03
Halozyme Therapeutics USD 42.25M 1.01M 2024-12
Incyte USD 325.69M 1.02M 2025-03
Ionis Pharmaceuticals USD 76M 12.08M 2025-03
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Pfizer USD 3.01B 1.27B 2025-03
Prothena USD 16.85M 88K 2024-12
Regeneron Pharmaceuticals USD 633M 159.2M 2025-03
Repligen USD 71.26M 10.93M 2025-03
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Teva Pharmaceutical Industries USD 952M 28M 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Neurocrine Biosciences 销售和管理费用 - 当前值，历史数据，预测，统计，图表和经济日历 - May 2025.